- Report
- September 2023
- 107 Pages
Asia Pacific
From €3098EUR$3,450USD£2,638GBP
- Report
- September 2023
- 112 Pages
Europe
From €3098EUR$3,450USD£2,638GBP
- Report
- September 2023
- 101 Pages
North America
From €2649EUR$2,950USD£2,256GBP
- Report
- September 2023
- 194 Pages
Global
From €4444EUR$4,950USD£3,785GBP
- Report
- March 2021
- 137 Pages
Global
From €4399EUR$4,900USD£3,747GBP
- Drug Pipelines
- January 2018
- 18 Pages
Global
From €8979EUR$10,000USD£7,646GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €8979EUR$10,000USD£7,646GBP
- Report
- November 2024
- 78 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- August 2023
- 87 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- August 2023
- 108 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- August 2023
- 110 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- August 2023
- 92 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- July 2023
- 87 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- March 2024
- 132 Pages
Global
From €853EUR$950USD£726GBP
- Report
- November 2024
- 90 Pages
Australia
From €1168EUR$1,301USD£995GBP
€1669EUR$1,859USD£1,421GBP

Live attenuated vaccines are a type of vaccine that use a weakened form of a virus or bacteria to stimulate an immune response. These vaccines are designed to replicate the natural infection process, allowing the body to develop immunity without the risk of serious illness. Live attenuated vaccines are typically administered orally or nasally, and are often used to protect against diseases such as measles, mumps, rubella, and rotavirus.
Live attenuated vaccines are generally considered to be safe and effective, and are often used in combination with other vaccines to provide broader protection. They are also cost-effective, as they require fewer doses than other types of vaccines.
Notable companies in the live attenuated vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis. Show Less Read more